Review of recent clinical studies with olanzapine.
Olanzapine is a novel antipsychotic agent displaying a unique and pleotrophic pharmacology, which distinguishes it from other existing treatments. Clinical investigations employing olanzapine have demonstrated a number of potential therapeutic advantages in reference not only to placebo but also to contemporary drug standards in the management of psychosis. This paper reviews data on the pharmacokinetics, efficacy and safety of olanzapine, its benefits for quality of life, and economic aspects to assist clinicians in determining where they can usefully employ it.
Tollefson
G D
GD
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.
Kuntz
A J
AJ
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001569:Benzodiazepines; D003024:Clozapine / Q000627:therapeutic use; D003866:Depressive Disorder / Q000150:complications / Q000188:drug therapy; D004351:Drug Resistance; D006801:Humans; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D011388:Prolactin / Q000378:metabolism; D011618:Psychotic Disorders / Q000188:drug therapy; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D018967:Risperidone / Q000627:therapeutic use; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy*
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D011388:Prolactin; D003024:Clozapine; D018967:Risperidone; D000077152:Olanzapine